What is Lifemd Inc's earnings per share (EPS)?

Lifemd Inc (LFMD) reported diluted earnings per share of $0.25 for fiscal year 2025. This represents a 141.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lifemd Inc Financials

LFMD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Lifemd Inc (LFMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Lifemd Inc has an operating margin of -4.0%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 13/100, suggesting thin profitability after operating expenses. This is up from -13.2% the prior year.

Growth

Lifemd Inc's revenue surged 25.3% year-over-year to $194.1M, reflecting rapid business expansion. This strong growth earns a score of 76/100.

Leverage

Lifemd Inc has a moderate D/E ratio of 2.04. This balance of debt and equity financing earns a leverage score of 60/100.

Liquidity

Lifemd Inc's current ratio of 1.25 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 20/100, which could limit financial flexibility.

Cash Flow

Lifemd Inc has a free cash flow margin of 3.3%, earning a moderate score of 33/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

100

Lifemd Inc earns a strong 62.0% return on equity (ROE), meaning it generates $62 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.

Piotroski F-Score Neutral

5/9

Lifemd Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

0.58x

For every $1 of reported earnings, Lifemd Inc generates $0.58 in operating cash flow ($8.3M OCF vs $14.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-5.6x

Lifemd Inc earns $-5.6 in operating income for every $1 of interest expense (-$7.7M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$194.1M

YoY+25.3%

5Y CAGR+39.1%

10Y CAGR+66.0%

Lifemd Inc generated $194.1M in revenue in fiscal year 2025. This represents an increase of 25.3% from the prior year.

EBITDA

-$6.7M

YoY+66.3%

Lifemd Inc's EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 66.3% from the prior year.

Net Income

$14.4M

YoY+167.0%

Lifemd Inc reported $14.4M in net income in fiscal year 2025. This represents an increase of 167.0% from the prior year.

EPS (Diluted)

$0.25

YoY+141.7%

Lifemd Inc earned $0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 141.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$6.4M

YoY-60.1%

Lifemd Inc generated $6.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 60.1% from the prior year.

Cash & Debt

$36.8M

YoY+5.1%

5Y CAGR+32.0%

10Y CAGR+65.9%

Lifemd Inc held $36.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

47M

YoY+10.6%

5Y CAGR+14.9%

Lifemd Inc had 47M shares outstanding in fiscal year 2025. This represents an increase of 10.6% from the prior year.

Margins & Returns

Gross Margin

85.7%

YoY-0.4pp

5Y CAGR+9.5pp

10Y CAGR+6.0pp

Lifemd Inc's gross margin was 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin

-4.0%

YoY+9.2pp

5Y CAGR+151.1pp

10Y CAGR+17.6pp

Lifemd Inc's operating margin was -4.0% in fiscal year 2025, reflecting core business profitability. This is up 9.2 percentage points from the prior year.

Net Margin

7.4%

YoY+21.2pp

5Y CAGR+164.7pp

10Y CAGR+12.5pp

Lifemd Inc's net profit margin was 7.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 21.2 percentage points from the prior year.

Return on Equity

62.0%

10Y CAGR+123.9pp

Lifemd Inc's ROE was 62.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$270K

Lifemd Inc spent $270K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$1.9M

YoY+27.8%

Lifemd Inc invested $1.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.8% from the prior year.

LFMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$194.1M+25.3%	$154.8M+1.5%	$152.5M+28.2%	$119.0M+28.2%	$92.9M+149.0%	$37.3M
Cost of Revenue	$27.7M+29.3%	$21.4M+13.4%	$18.9M+1.2%	$18.7M+3.7%	$18.0M+103.1%	$8.9M
Gross Profit	$166.3M+24.7%	$133.4M-0.2%	$133.6M+33.2%	$100.4M+34.0%	$74.9M+163.4%	$28.4M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$57.9M0.0%	$57.9M+12.1%	$51.7M+10.1%	$47.0M+18.8%	$39.5M-12.1%	$45.0M
Operating Income	-$7.7M+62.4%	-$20.4M-40.8%	-$14.5M+66.7%	-$43.4M+20.0%	-$54.3M+6.1%	-$57.8M
Interest Expense	$1.4M-37.4%	$2.2M-16.2%	$2.6M+103.5%	$1.3M-57.7%	$3.0M+81.1%	$1.7M
Income Tax	$46K-92.4%	$598K+39.7%	$428K+18.7%	$361K+4584.4%	$8K-93.7%	$123K
Net Income	$14.4M+167.0%	-$21.4M-3.9%	-$20.6M+54.8%	-$45.5M+25.2%	-$60.9M-3.8%	-$58.6M
EPS (Diluted)	$0.25+141.7%	$-0.60+14.3%	$-0.70+55.4%	$-1.57+31.4%	$-2.29+48.4%	$-4.44

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$7.1M-88.2%	$60.2M-4.0%	$62.7M-2.3%	$64.1M+850.7%	$6.7M-87.3%	$53.3M+5.2%	$50.7M+14.8%	$44.1M
Cost of Revenue	$4.2M-42.9%	$7.4M-0.3%	$7.4M-14.0%	$8.6M+27.1%	$6.8M+35.7%	$5.0M-0.2%	$5.0M+9.2%	$4.6M
Gross Profit	$2.8M-94.6%	$52.8M-4.5%	$55.2M-0.4%	$55.5M+98314.8%	-$56K-100.1%	$48.3M+5.7%	$45.6M+15.4%	$39.5M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$6.7M-59.5%	$16.6M-5.6%	$17.6M+3.0%	$17.1M+184.0%	$6.0M-66.8%	$18.1M-2.2%	$18.5M+21.0%	$15.3M
Operating Income	-$6.2M-216.0%	-$2.0M-336.1%	-$452K-146.3%	$974K+124.8%	-$3.9M+1.7%	-$4.0M+36.6%	-$6.3M-2.2%	-$6.2M
Interest Expense	-$191K-172.7%	$262K-60.4%	$663K+5.9%	$626K+3.1%	$608K+8.8%	$559K+5.1%	$531K+11.3%	$478K
Income Tax	N/A	$169K	N/A	N/A	N/A	$233K	N/A	N/A
Net Income	$20.0M+624.5%	-$3.8M-135.0%	-$1.6M-781.3%	-$184K+94.1%	-$3.1M+33.3%	-$4.7M+32.3%	-$6.9M-1.6%	-$6.8M
EPS (Diluted)	N/A	$-0.10-100.0%	$-0.05-150.0%	$-0.02	N/A	$-0.13+31.6%	$-0.190.0%	$-0.19

LFMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$70.4M-7.5%	$76.1M+30.1%	$58.5M+127.9%	$25.7M-48.6%	$49.9M+272.5%	$13.4M
Current Assets	$51.8M-1.0%	$52.4M+22.9%	$42.6M+276.7%	$11.3M-74.8%	$44.9M+261.9%	$12.4M
Cash & Equivalents	$36.8M+5.1%	$35.0M+5.6%	$33.1M+737.3%	$4.0M-90.4%	$41.3M+350.2%	$9.2M
Inventory	$2.8M-0.9%	$2.8M+1.4%	$2.8M-25.5%	$3.7M+129.1%	$1.6M+27.9%	$1.3M
Accounts Receivable	$9.3M-11.0%	$10.5M+66.9%	$6.3M+121.0%	$2.8M+189.2%	$980K-1.8%	$998K
Goodwill	N/A	N/A	N/A	$8.0M	$0	N/A
Total Liabilities	$47.3M-43.5%	$83.7M+58.1%	$52.9M+60.5%	$33.0M+36.8%	$24.1M+69.5%	$14.2M
Current Liabilities	$41.6M-38.3%	$67.4M+93.8%	$34.8M+10.9%	$31.4M+37.5%	$22.8M+63.8%	$13.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$23.2M+354.9%	-$9.1M-359.1%	$3.5M+130.8%	-$11.4M-150.1%	$22.7M+1087.9%	-$2.3M
Retained Earnings	-$228.6M+4.7%	-$239.9M-11.9%	-$214.3M-12.4%	-$190.6M-34.3%	-$141.9M-77.1%	-$80.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$70.4M+6.7%	$66.0M-10.3%	$73.6M-0.1%	$73.6M-3.3%	$76.1M+4.9%	$72.6M+13.7%	$63.8M+3.8%	$61.5M
Current Assets	$51.8M+26.2%	$41.1M-16.2%	$49.0M-1.9%	$50.0M-4.6%	$52.4M+7.6%	$48.7M+8.0%	$45.1M+1.5%	$44.4M
Cash & Equivalents	$36.8M+54.7%	$23.8M-34.3%	$36.2M+5.3%	$34.4M-1.7%	$35.0M-6.9%	$37.6M+5.3%	$35.7M+1.7%	$35.1M
Inventory	$2.8M-19.2%	$3.4M+5.6%	$3.3M+9.6%	$3.0M+6.1%	$2.8M+5.7%	$2.6M+28.4%	$2.1M-13.2%	$2.4M
Accounts Receivable	$9.3M+0.7%	$9.2M+26.1%	$7.3M-28.1%	$10.2M-2.5%	$10.5M+72.8%	$6.0M+6.7%	$5.7M+6.2%	$5.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$47.3M-24.5%	$62.6M-14.4%	$73.2M-1.1%	$74.0M-11.5%	$83.7M+6.5%	$78.5M+19.2%	$65.9M+9.5%	$60.2M
Current Liabilities	$41.6M-26.6%	$56.7M-10.8%	$63.5M+4.3%	$60.9M-9.6%	$67.4M+14.3%	$59.0M+14.1%	$51.6M+15.6%	$44.7M
Long-Term Debt	N/A	N/A	$15.9M	N/A	N/A	N/A	N/A	N/A
Total Equity	$23.2M+1661.8%	$1.3M+173.7%	-$1.8M+23.5%	-$2.3M+74.4%	-$9.1M-17.7%	-$7.7M-83.5%	-$4.2M-397.6%	-$845K
Retained Earnings	-$228.6M+7.7%	-$247.8M-3.9%	-$238.5M-1.2%	-$235.6M+1.8%	-$239.9M-1.9%	-$235.4M-2.6%	-$229.5M-3.4%	-$221.8M

LFMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$8.3M-52.7%	$17.5M+98.6%	$8.8M+138.5%	-$22.9M+30.7%	-$33.1M-172.7%	-$12.1M
Capital Expenditures	$1.9M+27.8%	$1.5M+618.0%	$204K-44.4%	$367K+48.2%	$247K	N/A
Free Cash Flow	$6.4M-60.1%	$16.0M+86.3%	$8.6M+137.0%	-$23.3M+30.1%	-$33.3M	N/A
Investing Cash Flow	$6.9M+159.9%	-$11.5M-32.1%	-$8.7M+37.2%	-$13.9M-308.7%	-$3.4M-326.3%	-$798K
Financing Cash Flow	-$13.4M-225.5%	-$4.1M-114.2%	$29.1M+5609.4%	-$528K-100.8%	$68.6M+226.8%	$21.0M
Dividends Paid	$3.1M0.0%	$3.1M0.0%	$3.1M0.0%	$3.1M+256.4%	$871K	N/A
Share Buybacks	$270K	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$3.3M-2129.6%	-$147K-101.7%	$8.6M+181.6%	$3.1M+185.9%	$1.1M-84.0%	$6.7M+47.5%	$4.5M-12.7%	$5.2M
Capital Expenditures	$155K-80.5%	$797K+0.2%	$796K+551.1%	$122K-38.2%	$198K-55.8%	$448K-30.3%	$642K+265.7%	$176K
Free Cash Flow	-$3.4M-263.8%	-$944K-112.0%	$7.8M+166.2%	$2.9M+236.6%	$875K-86.0%	$6.3M+60.4%	$3.9M-22.5%	$5.0M
Investing Cash Flow	$17.1M+574.9%	-$3.6M+2.8%	-$3.7M-29.0%	-$2.9M-5.4%	-$2.7M+22.1%	-$3.5M-11.5%	-$3.1M-43.0%	-$2.2M
Financing Cash Flow	-$789K+90.9%	-$8.7M-180.2%	-$3.1M-282.1%	-$813K+13.1%	-$935K+29.2%	-$1.3M-62.0%	-$815K+22.2%	-$1.0M
Dividends Paid	$777K0.0%	$777K0.0%	$777K0.0%	$777K0.0%	$777K0.0%	$777K0.0%	$777K0.0%	$777K
Share Buybacks	N/A	$270K	N/A	N/A	N/A	N/A	N/A	N/A

LFMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	85.7%-0.4pp	86.2%-1.5pp	87.6%+3.3pp	84.3%+3.7pp	80.6%+4.4pp	76.2%
Operating Margin	-4.0%+9.2pp	-13.2%-3.7pp	-9.5%+27.0pp	-36.5%+22.0pp	-58.5%+96.6pp	-155.0%
Net Margin	7.4%+21.2pp	-13.8%-0.3pp	-13.5%+24.8pp	-38.3%+27.3pp	-65.6%+91.7pp	-157.3%
Return on Equity	62.0%	N/A	-587.6%	N/A	-267.8%	N/A
Return on Assets	20.4%+48.5pp	-28.1%+7.1pp	-35.2%+142.2pp	-177.4%-55.4pp	-122.0%+315.6pp	-437.6%
Current Ratio	1.25+0.5	0.78-0.4	1.22+0.9	0.36-1.6	1.97+1.1	0.89
Debt-to-Equity	2.04+11.3	-9.21-24.3	15.10+18.0	-2.89-4.0	1.06+7.2	-6.18
FCF Margin	3.3%-7.1pp	10.4%+4.7pp	5.7%+25.2pp	-19.6%+16.3pp	-35.9%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	40.2%-47.5pp	87.7%-0.4pp	88.1%+1.6pp	86.5%+87.4pp	-0.8%-91.4pp	90.6%+0.5pp	90.1%+0.5pp	89.6%
Operating Margin	-87.9%-84.6pp	-3.3%-2.6pp	-0.7%-2.2pp	1.5%+59.8pp	-58.2%-50.7pp	-7.5%+5.0pp	-12.4%+1.5pp	-14.0%
Net Margin	282.0%+288.3pp	-6.3%-3.7pp	-2.6%-2.3pp	-0.3%+45.8pp	-46.1%-37.3pp	-8.7%+4.8pp	-13.6%+1.8pp	-15.3%
Return on Equity	86.2%+375.8pp	-289.6%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	28.3%+34.1pp	-5.8%-3.6pp	-2.2%-1.9pp	-0.3%+3.8pp	-4.1%+2.3pp	-6.4%+4.4pp	-10.8%+0.2pp	-11.0%
Current Ratio	1.25+0.5	0.73-0.0	0.77-0.0	0.82+0.0	0.78-0.0	0.83-0.0	0.87-0.1	0.99
Debt-to-Equity	2.04-45.6	47.64+56.6	-8.92+22.9	-31.78-22.6	-9.21+1.0	-10.17+5.5	-15.66+55.5	-71.17
FCF Margin	-48.5%-47.0pp	-1.6%-14.1pp	12.5%+7.9pp	4.6%-8.4pp	13.0%+1.2pp	11.7%+4.0pp	7.7%-3.7pp	11.4%

Similar Companies

Mobile-health Network Solutions MNDR

$3.1M

Simulations Plus Inc SLP

$241.6M

Health Catalyst HCAT

$86.1M

Sophia Genetics Sa SOPH

$361.2M

Carecloud Inc CCLD

$142.4M

Frequently Asked Questions

What is Lifemd Inc's annual revenue?

Lifemd Inc (LFMD) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lifemd Inc's revenue growing?

Lifemd Inc (LFMD) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.

Is Lifemd Inc profitable?

Yes, Lifemd Inc (LFMD) reported a net income of $14.4M in fiscal year 2025, with a net profit margin of 7.4%.

What is Lifemd Inc's EBITDA?

Lifemd Inc (LFMD) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lifemd Inc's gross margin?

Lifemd Inc (LFMD) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lifemd Inc's operating margin?

Lifemd Inc (LFMD) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lifemd Inc's net profit margin?

Lifemd Inc (LFMD) had a net profit margin of 7.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Lifemd Inc's return on equity (ROE)?

Lifemd Inc (LFMD) has a return on equity of 62.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lifemd Inc's free cash flow?

Lifemd Inc (LFMD) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lifemd Inc's operating cash flow?

Lifemd Inc (LFMD) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lifemd Inc's total assets?

Lifemd Inc (LFMD) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lifemd Inc's capital expenditures?

Lifemd Inc (LFMD) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Lifemd Inc buy back shares?

Yes, Lifemd Inc (LFMD) spent $270K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Lifemd Inc have outstanding?

Lifemd Inc (LFMD) had 47M shares outstanding as of fiscal year 2025.

What is Lifemd Inc's current ratio?

Lifemd Inc (LFMD) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.

What is Lifemd Inc's debt-to-equity ratio?

Lifemd Inc (LFMD) had a debt-to-equity ratio of 2.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lifemd Inc's return on assets (ROA)?

Lifemd Inc (LFMD) had a return on assets of 20.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lifemd Inc's Piotroski F-Score?

Lifemd Inc (LFMD) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lifemd Inc's earnings high quality?

Lifemd Inc (LFMD) has an earnings quality ratio of 0.58x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lifemd Inc cover its interest payments?

Lifemd Inc (LFMD) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Lifemd Inc?

Lifemd Inc (LFMD) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.